Janssen Prods Drug Patent Portfolio
Janssen Prods owns 7 orange book drugs protected by 54 US patents with Edurant Ped having the least patent protection, holding only 2 patents. And Prezista with maximum patent protection, holding 26 patents. Given below is the list of Janssen Prods's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10786518 | Compositions and methods of treating HIV | 19 Jul, 2038 | Active |
| US11065198 | Dispersible compositions | 23 Oct, 2037 | Active |
| US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent | 06 Oct, 2032 | Active |
| US8754065 | Tenofovir alafenamide hemifumarate | 15 Aug, 2032 | Active |
| US9296769 | Tenofovir alafenamide hemifumarate | 15 Aug, 2032 | Active |
| US8148399 | Macrocyclic inhibitors of hepatitis C virus | 05 Sep, 2029 | Active |
| US8148374 | Modulators of pharmacokinetic properties of therapeutics | 03 Sep, 2029 | Active |
| US8895557 | Pharmaceutical formulations of ecteinascidin compounds | 07 Jul, 2028 | Active |
| US8895557 | Pharmaceutical formulations of ecteinascidin compounds | 07 Jan, 2028 | Active |
| US7700645 | Pseudopolymorphic forms of a HIV protease inhibitor | 26 Jun, 2027 | Active |
| US7700645 | Pseudopolymorphic forms of a HIV protease inhibitor | 26 Dec, 2026 | Active |
| US8349869 | Macrocylic inhibitors of hepatitis C virus | 28 Jul, 2026 | Active |
| US8741926 | Macrocyclic inhibitors of hepatitis C virus | 28 Jul, 2026 | Active |
| US8754106 | Macrocyclic inhibitors of hepatitis C virus | 28 Jul, 2026 | Active |
| US9040562 | Macrocyclic inhibitors of hepatitis C virus | 28 Jul, 2026 | Active |
| US9353103 | Macrocyclic inhibitors of hepatitis C virus | 28 Jul, 2026 | Active |
| US9623022 | Macrocyclic inhibitors of hepatitis C virus | 28 Jul, 2026 | Active |
| US9856265 | Macrocyclic inhibitors of hepatitis C virus | 28 Jul, 2026 | Active |
| US7125879 | HIV inhibiting pyrimidines derivatives | 21 Oct, 2025 | Active |
| US7671032 | HCV NS-3 serine protease inhibitors | 19 May, 2025 | Active |
| US7125879 | HIV inhibiting pyrimidines derivatives | 21 Apr, 2025 | Active |
| US7390791 | Prodrugs of phosphonate nucleotide analogues | 17 Apr, 2025 | Active |
| US8518987 | Pseudopolymorphic forms of a HIV protease inhibitor | 16 Aug, 2024 | Expired |
| US8518987 | Pseudopolymorphic forms of a HIV protease inhibitor | 16 Feb, 2024 | Expired |
| US7638522 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile | 14 Apr, 2023 | Expired |
| US8080551 | HIV inhibiting pyrimidines derivatives | 11 Apr, 2023 | Expired |
| US8101629 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | 09 Aug, 2022 | Expired |
| US7803788 | Prodrugs of phosphonate nucoleotide analogues | 02 Feb, 2022 | Expired |
| US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers | 09 Mar, 2021 | Expired |
| US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents | 26 Feb, 2021 | Expired |
| US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 04 Nov, 2020 | Expired |
| US7470506 | Fitness assay and associated methods | 23 Dec, 2019 | Expired |
| US8597876 | Method of treating HIV infection | 23 Dec, 2019 | Expired |
| US9889115 | Fitness assay and associated methods | 23 Dec, 2019 | Expired |
| US7067522 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | 20 Dec, 2019 | Expired |
| US7470506 | Fitness assay and associated methods | 23 Jun, 2019 | Expired |
| US8597876 | Method of treating HIV infection | 23 Jun, 2019 | Expired |
| US9889115 | Fitness assay and associated methods | 23 Jun, 2019 | Expired |
| USRE43596 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | 09 Nov, 2017 | Expired |
| USRE43596 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | 09 May, 2017 | Expired |
| USRE42889 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | 19 Apr, 2017 | Expired |
| USRE43802 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | 19 Apr, 2017 | Expired |
| US6037157 | Method for improving pharmacokinetics | 26 Dec, 2016 | Expired |
| US6703403 | Method for improving pharmacokinetics | 26 Dec, 2016 | Expired |
| USRE42889 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | 19 Oct, 2016 | Expired |
| USRE43802 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | 19 Oct, 2016 | Expired |
| US6037157 | Method for improving pharmacokinetics | 26 Jun, 2016 | Expired |
| US6703403 | Method for improving pharmacokinetics | 26 Jun, 2016 | Expired |
| US5843946 | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | 01 Jun, 2016 | Expired |
| US5843946 | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | 01 Dec, 2015 | Expired |
| US6248775 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | 13 Feb, 2015 | Expired |
| US6248775 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | 13 Aug, 2014 | Expired |
| US6335460 | α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors | 25 Feb, 2013 | Expired |
| US6335460 | α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors | 25 Aug, 2012 | Expired |
Latest Legal Activities on Janssen Prods's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Janssen Prods.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 22 Jan, 2024 | US8080551 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2023 | US8148374 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 07 Aug, 2023 | US8080551 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Jul, 2023 | US8101629 |
|
Expire Patent
Critical
| 25 Jul, 2022 | US8754106 |
|
Expire Patent
Critical
| 11 Jul, 2022 | US8741926 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jul, 2022 | US9040562 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 May, 2022 | US8895557 |
|
Expire Patent
Critical
| 21 Mar, 2022 | US9889115 |
|
Expire Patent
Critical
| 21 Mar, 2022 | US9889115 |
|
Maintenance Fee Reminder Mailed
Critical
| 07 Feb, 2022 | US8754106 |
|
Expire Patent
Critical
| 07 Feb, 2022 | US9856265 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jan, 2022 | US10039718 |
|
Maintenance Fee Reminder Mailed
Critical
| 24 Jan, 2022 | US8741926 |
|
Expire Patent
Critical
| 10 Jan, 2022 | US8597876 (Litigated) |
Janssen Prods's Drug Patent Litigations
Janssen Prods's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 05, 2001, against patent number US6642245. The petitioner , challenged the validity of this patent, with DIONNE as the respondent. Click below to track the latest information on how companies are challenging Janssen Prods's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8518987 | April, 2015 |
Terminated-Denied
(16 Oct, 2015)
| Janssen Sciences Ireland UC | Lupin Limited |
| US6703396 | April, 2002 |
Decision
(04 Apr, 2002)
| DIONNE | |
| US6642245 | July, 2001 |
Decision
(05 Jul, 2001)
| DIONNE | |
Janssen Prods Drug Patents' Oppositions Filed in EPO
Janssen Prods drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 09, 2012, by Hamm, Volker. This opposition was filed on patent number EP05108086A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16180589A | Oct, 2020 | Cooke, Richard | Granted and Under Opposition |
| EP16180589A | Oct, 2020 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP16180589A | Jan, 2020 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP14168686A | Apr, 2018 | Cooke, Richard | Opposition rejected |
| EP13164300A | Jan, 2018 | Georg Kalhammer/Stephan Teipel | Granted and Under Opposition |
| EP13164300A | Jan, 2018 | Aechter, Bernd | Granted and Under Opposition |
| EP13164300A | Jan, 2018 | Cooke, Richard | Granted and Under Opposition |
| EP12753867A | Jul, 2017 | FRKelly | Granted and Under Opposition |
| EP12753867A | Jul, 2017 | Sandoz GmbH | Granted and Under Opposition |
| EP12753867A | Jul, 2017 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP12167591A | May, 2017 | Cooke, Richard | Revoked |
| EP12167590A | May, 2017 | Cooke, Richard | Revoked |
| EP12167590A | May, 2017 | Teva Pharmaceutical Industries LTD. | Revoked |
| EP12167591A | May, 2017 | Teva Pharmaceutical Industries LTD. | Revoked |
| EP12167589A | May, 2017 | Cooke, Richard | Granted and Under Opposition |
| EP12167589A | May, 2017 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP12167596A | Apr, 2017 | Cooke, Richard | Revoked |
| EP12167596A | Apr, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP09739981A | Jun, 2016 | Cooke, Richard | Revoked |
| EP09739981A | Jun, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP10703766A | Apr, 2016 | Cooke, Richard | Revoked |
| EP10703766A | Apr, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP07836007A | Mar, 2016 | Trösch, Dominique | Granted and Under Opposition |
| EP07836007A | Mar, 2016 | Georg Kalhammer/Stephan Teipel | Granted and Under Opposition |
| EP07836007A | Mar, 2016 | Teva Pharmaceutical Industries LTD. | Granted and Under Opposition |
| EP04787096A | Jan, 2016 | Page White & Farrer Limited | Patent maintained as amended |
| EP01961695A | Nov, 2015 | HEXAL PHARMA AG | Patent maintained as amended |
| EP01961695A | Nov, 2015 | Strawman Limited | Patent maintained as amended |
| EP01961695A | Nov, 2015 | Teva Pharmaceutical Industries Ltd | Patent maintained as amended |
| EP01961695A | Nov, 2015 | Swindell & Pearson Limited | Patent maintained as amended |
| EP10180831A | Mar, 2015 | Wittkopp, Alexander | Patent maintained as amended |
| EP03753571A | Mar, 2015 | Wittkopp, Alexander | Patent maintained as amended |
| EP03753571A | Mar, 2015 | Strawman Limited | Patent maintained as amended |
| EP10180831A | Mar, 2015 | Strawman Limited | Patent maintained as amended |
| EP10180831A | Mar, 2015 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Patent maintained as amended |
| EP03753571A | Mar, 2015 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Patent maintained as amended |
| EP05108086A | Feb, 2012 | Hamm, Volker | The patent has been limited |
Janssen Prods's Family Patents
Janssen Prods drugs have patent protection in a total of 64 countries. It's US patent count contributes only to 13.0% of its total global patent coverage. 16 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Janssen Prods Drug List
Given below is the complete list of Janssen Prods's drugs and the patents protecting them.
1. Edurant
Edurant is protected by 7 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7125879
(Pediatric)
| HIV inhibiting pyrimidines derivatives |
21 Oct, 2025
(9 months from now)
| Active |
| US7125879 | HIV inhibiting pyrimidines derivatives |
21 Apr, 2025
(3 months from now)
| Active |
| US7638522 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
14 Apr, 2023
(1 year, 8 months ago)
| Expired |
| US8080551 | HIV inhibiting pyrimidines derivatives |
11 Apr, 2023
(1 year, 8 months ago)
| Expired |
| US8101629 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
09 Aug, 2022
(2 years ago)
| Expired |
| US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
26 Feb, 2021
(3 years ago)
| Expired |
| US7067522 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
20 Dec, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edurant's drug page
2. Edurant Ped
Edurant Ped is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11065198 | Dispersible compositions |
23 Oct, 2037
(12 years from now)
| Active |
| US7125879 | HIV inhibiting pyrimidines derivatives |
21 Apr, 2025
(3 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edurant Ped's drug page
3. Olysio
Olysio is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8148399 | Macrocyclic inhibitors of hepatitis C virus |
05 Sep, 2029
(4 years from now)
| Active |
| US8349869 | Macrocylic inhibitors of hepatitis C virus |
28 Jul, 2026
(1 year, 6 months from now)
| Active |
| US8741926 | Macrocyclic inhibitors of hepatitis C virus |
28 Jul, 2026
(1 year, 6 months from now)
| Active |
| US8754106 | Macrocyclic inhibitors of hepatitis C virus |
28 Jul, 2026
(1 year, 6 months from now)
| Active |
| US9040562 | Macrocyclic inhibitors of hepatitis C virus |
28 Jul, 2026
(1 year, 6 months from now)
| Active |
| US9353103 | Macrocyclic inhibitors of hepatitis C virus |
28 Jul, 2026
(1 year, 6 months from now)
| Active |
| US9623022 | Macrocyclic inhibitors of hepatitis C virus |
28 Jul, 2026
(1 year, 6 months from now)
| Active |
| US9856265 | Macrocyclic inhibitors of hepatitis C virus |
28 Jul, 2026
(1 year, 6 months from now)
| Active |
| US7671032 | HCV NS-3 serine protease inhibitors |
19 May, 2025
(4 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Olysio's drug page
4. Prezcobix
Prezcobix is protected by 19 patents, out of which 15 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
06 Oct, 2032
(7 years from now)
| Active |
| US8148374 | Modulators of pharmacokinetic properties of therapeutics |
03 Sep, 2029
(4 years from now)
| Active |
| US7700645
(Pediatric)
| Pseudopolymorphic forms of a HIV protease inhibitor |
26 Jun, 2027
(2 years from now)
| Active |
| US7700645 | Pseudopolymorphic forms of a HIV protease inhibitor |
26 Dec, 2026
(1 year, 11 months from now)
| Active |
| US8518987
(Pediatric)
| Pseudopolymorphic forms of a HIV protease inhibitor |
16 Aug, 2024
(4 months ago)
| Expired |
| US8518987 | Pseudopolymorphic forms of a HIV protease inhibitor |
16 Feb, 2024
(10 months ago)
| Expired |
| US7470506
(Pediatric)
| Fitness assay and associated methods |
23 Dec, 2019
(5 years ago)
| Expired |
| US8597876
(Pediatric)
| Method of treating HIV infection |
23 Dec, 2019
(5 years ago)
| Expired |
| US7470506 | Fitness assay and associated methods |
23 Jun, 2019
(5 years ago)
| Expired |
| US8597876 | Method of treating HIV infection |
23 Jun, 2019
(5 years ago)
| Expired |
| US9889115 | Fitness assay and associated methods |
23 Jun, 2019
(5 years ago)
| Expired |
| USRE43596
(Pediatric)
| α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
09 Nov, 2017
(7 years ago)
| Expired |
| USRE43596 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
09 May, 2017
(7 years ago)
| Expired |
| USRE42889
(Pediatric)
| α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
19 Apr, 2017
(7 years ago)
| Expired |
| USRE43802
(Pediatric)
| α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
19 Apr, 2017
(7 years ago)
| Expired |
| USRE42889 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
19 Oct, 2016
(8 years ago)
| Expired |
| USRE43802 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
19 Oct, 2016
(8 years ago)
| Expired |
| US5843946
(Pediatric)
| α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
01 Jun, 2016
(8 years ago)
| Expired |
| US5843946 | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
01 Dec, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prezcobix's drug page
5. Prezista
Prezista is protected by 26 patents, out of which 24 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7700645
(Pediatric)
| Pseudopolymorphic forms of a HIV protease inhibitor |
26 Jun, 2027
(2 years from now)
| Active |
| US7700645 | Pseudopolymorphic forms of a HIV protease inhibitor |
26 Dec, 2026
(1 year, 11 months from now)
| Active |
| US8518987
(Pediatric)
| Pseudopolymorphic forms of a HIV protease inhibitor |
16 Aug, 2024
(4 months ago)
| Expired |
| US8518987 | Pseudopolymorphic forms of a HIV protease inhibitor |
16 Feb, 2024
(10 months ago)
| Expired |
| US7470506
(Pediatric)
| Fitness assay and associated methods |
23 Dec, 2019
(5 years ago)
| Expired |
| US8597876
(Pediatric)
| Method of treating HIV infection |
23 Dec, 2019
(5 years ago)
| Expired |
| US9889115
(Pediatric)
| Fitness assay and associated methods |
23 Dec, 2019
(5 years ago)
| Expired |
| US7470506 | Fitness assay and associated methods |
23 Jun, 2019
(5 years ago)
| Expired |
| US8597876 | Method of treating HIV infection |
23 Jun, 2019
(5 years ago)
| Expired |
| US9889115 | Fitness assay and associated methods |
23 Jun, 2019
(5 years ago)
| Expired |
| USRE43596
(Pediatric)
| α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
09 Nov, 2017
(7 years ago)
| Expired |
| USRE43596 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
09 May, 2017
(7 years ago)
| Expired |
| USRE42889
(Pediatric)
| α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
19 Apr, 2017
(7 years ago)
| Expired |
| USRE43802
(Pediatric)
| α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
19 Apr, 2017
(7 years ago)
| Expired |
| US6037157
(Pediatric)
| Method for improving pharmacokinetics |
26 Dec, 2016
(8 years ago)
| Expired |
| US6703403
(Pediatric)
| Method for improving pharmacokinetics |
26 Dec, 2016
(8 years ago)
| Expired |
| USRE42889 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
19 Oct, 2016
(8 years ago)
| Expired |
| USRE43802 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
19 Oct, 2016
(8 years ago)
| Expired |
| US6037157 | Method for improving pharmacokinetics |
26 Jun, 2016
(8 years ago)
| Expired |
| US6703403 | Method for improving pharmacokinetics |
26 Jun, 2016
(8 years ago)
| Expired |
| US5843946
(Pediatric)
| α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
01 Jun, 2016
(8 years ago)
| Expired |
| US5843946 | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
01 Dec, 2015
(9 years ago)
| Expired |
| US6248775
(Pediatric)
| α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
13 Feb, 2015
(9 years ago)
| Expired |
| US6248775 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
13 Aug, 2014
(10 years ago)
| Expired |
| US6335460
(Pediatric)
| α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors |
25 Feb, 2013
(11 years ago)
| Expired |
| US6335460 | α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors |
25 Aug, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prezista's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Symtuza
Symtuza is protected by 14 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10786518 | Compositions and methods of treating HIV |
19 Jul, 2038
(13 years from now)
| Active |
| US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
06 Oct, 2032
(7 years from now)
| Active |
| US8754065 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
| US9296769 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
| US8148374 | Modulators of pharmacokinetic properties of therapeutics |
03 Sep, 2029
(4 years from now)
| Active |
| US7700645 | Pseudopolymorphic forms of a HIV protease inhibitor |
26 Dec, 2026
(1 year, 11 months from now)
| Active |
| US7390791 | Prodrugs of phosphonate nucleotide analogues |
17 Apr, 2025
(3 months from now)
| Active |
| US8518987 | Pseudopolymorphic forms of a HIV protease inhibitor |
16 Feb, 2024
(10 months ago)
| Expired |
| US7803788 | Prodrugs of phosphonate nucoleotide analogues |
02 Feb, 2022
(2 years ago)
| Expired |
| US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Mar, 2021
(3 years ago)
| Expired |
| US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 Nov, 2020
(4 years ago)
| Expired |
| US7470506 | Fitness assay and associated methods |
23 Jun, 2019
(5 years ago)
| Expired |
| US8597876 | Method of treating HIV infection |
23 Jun, 2019
(5 years ago)
| Expired |
| US9889115 | Fitness assay and associated methods |
23 Jun, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symtuza's drug page
7. Yondelis
Yondelis is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8895557
(Pediatric)
| Pharmaceutical formulations of ecteinascidin compounds |
07 Jul, 2028
(3 years from now)
| Active |
| US8895557 | Pharmaceutical formulations of ecteinascidin compounds |
07 Jan, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yondelis's drug page